Kendle International Inc

Kendle International — Investor Presentation (August 2005)

29 slides from Kendle International's investor presentation, Aug 8, 2005

  1. Slide 1: Kendle on the move August 2005

    Kendle on the move August 2005

  2. Slide 2: Safe Harbor

    Safe Harbor Information herein contains forward-looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management's expectations and are subject to risks and uncertainties that could c

  3. Slide 3: Kendle Vision

    Kendle Vision North America + Europe + Asia/Pacific + Latin America + Africa

  4. Slide 4: Kendle Vision: On the path to shareholder value

    Kendle Vision On the path to shareholder value; striving to outperform the CRO sector Platform for growth Clear imperatives and organizational realignment have accelerated recovery Percentage sales growth in 2004 tripled the reported industry average Future challenges Return to double-digit operatin

  5. Slide 5: The Path to Shareholder Value

    The Path to Shareholder Value Continued future growth Clinical Development Phase I - IV Accelerated organic growth Recovery Commercialization Pre-clinical Competency Broader acquisition strategy Adjacent acquisitions Share growth Phase I - IV Imperatives Organizational realignment Longer term Mid te

  6. Slide 6: Market Benchmarks

    Market Benchmarks North America + Europe + Asia/Pacific + Latin America + Africa

  7. Slide 7: Strong Growth in Gross Sales

    2003 Strong Growth in Gross Sales $Million Q1 Q2 Q3 Q4 70 70 58 53 53 47 55 33 73 80 2004 2005 +38% +38%

  8. Slide 8: Strong Growth in Net Sales

    Strong Growth in Net Sales $Million 63 62 53 51 38 36 53 21 66 70 2003 2004 2005 Q1 Q2 Q3 Q4 +29% +32%

  9. Slide 9: Growth in Net Revenues vs Peer Group

    Growth in Net Revenues Peer* Group Kendle 12.7% 16.9% Q1 2005 * Peer Group includes PPD, Parexel, PRA and ICON. Peer* Group Kendle 12.8% 21.2% Q2 2005 Peer* Group Kendle 10.6% 10.7% 2004

  10. Slide 10: Operating Margin Comparison

    Operating Margin Comparison Peer* Group Kendle 14.4% 6.0% Q1 2005 * Peer Group includes PPD, Parexel, PRA and ICON. Peer* Group Kendle 11.8% 7.3% Q2 2005 Peer* Group Kendle 13.4% 3.9% 2004

  11. Slide 11: Growth Indicators

    Growth Indicators North America + Europe + Asia/Pacific + Latin America + Africa

  12. Slide 12: Growth in Number of RFPs Received

    Growth in Number of RFPs Received +14% 2004 2003 Large $ value awards 2005 +28% - -14.4%

  13. Slide 13: Improvement in Quality and Value of RFPs

    Improvement in Quality and Value of RFPs Growth in quality and alignment of RFPs to Kendle core competencies Q1 '05 vs. Q1 '04 and Q2 '05 vs. Q2 '04 Total RFPs Service Brand RFPs Multiple Service RFPs

  14. Slide 14: Growth in Customer MSAs Versus Prior Year

    Growth in Customer MSAs Versus Prior Year 2003 2004 More strategic relationships leading to win/win efficiencies +26% +42%

  15. Slide 15: Kendle: Performance Where it Counts

    Kendle Performance Where it Counts North America + Europe + Asia/Pacific + Latin America ‘Africa

  16. Slide 16: Project Leadership at Kendle

    Kendle Project Leader Project Leadership at Kendle Enhanced Communication Proactive Solution Focus Direct Access to Senior Management Full Accountability Winner of Pharmaceutical Times Project Team of the Year, 2005

  17. Slide 17: Staying Ahead of the Industry Trend

    Staying Ahead of the Industry Trend Oncology CNS Leadership within therapeutic areas: Adjunctive therapy in Oncology Inflammation development experience best in class Suite of Respiratory studies Delivery of challenging studies e.g: pediatric GERD Therapeutic expertise Project portfolio aligned with

  18. Slide 18: Strong Business Mix in Q2 2005

    Strong Business Mix in Q2 2005 Top five customers represented 34% of revenue and 51% of gross sales Revenue distribution 56% North America, 40% Europe and 4% Asia-Pacific Biotech represented approximately one-third of new business awards Awards in Oncology and CNS therapy areas showing growth above

  19. Slide 19: Key Issues and Solutions

    Key Issues and Solutions

  20. Slide 20: 1. Translating Strong Backlog Into Results

    1. Translating Strong Backlog Into Results Operating Margin Leveraging SGA Preferred Customer Efficiencies Process Improvement 10% 14%

  21. Slide 21: 2. Punching More Than Our Weight

    2. Punching More Than Our Weight New geography offers new capacity - Romania, Bulgaria, Peru (2004) and India, South Africa (2005) Geographic expansion targets for review include LA, CEE as a priority and Asia-Pacific as secondary opportunity Acquisition opportunities to focus on adjacencies aligned

  22. Slide 22: Financial Results: Three Months Ended June 30

    NET SERVICE REVENUES* OPERATING INCOME* OPERATING MARGIN DILUTED EARNINGS PER SHARE NORTH AMERICAN REVENUE % Financial Results THREE MONTHS ENDED June 30 2005 2004 $41,217 $287 0.6% $0.02 59% $49,965 $3,652 7.3% $0.10** 56% *(000s) **Includes one-time, non-cash charge to reflect the write-off of def

  23. Slide 23: Financial Results: Six Months Ended June 30

    NET SERVICE REVENUES* OPERATING INCOME* OPERATING MARGIN DILUTED EARNINGS PER SHARE NORTH AMERICAN REVENUE % Financial Results SIX MONTHS ENDED June 30 2005 2004 $82,003 $983 1.2% $0.07 60% $97,652 $6,501 6.7% $0.26** 56% *(000s) **Includes one-time, non-cash charge to reflect the write-off of defer

  24. Slide 24: Financial Highlights Q2 2005

    Financial Highlights Q2 2005 OPERATING CASH FLOW CASH AND AVAILABLE-FOR-SALE SECURITIES WORKING CAPITAL TOTAL ASSETS CREDIT FACILITY DEBT SHAREHOLDERS' EQUITY $3.1 million $29.9 million $45.3 million $156.0 million $5.5 million $104.8 million

  25. Slide 25: 2005 Guidance

    2005 Guidance 2004 2005 est Growth Net Service Revenue* $172.9 $200 - $210 15.7% - 21.5% Pro forma EPS** $0.25 $0.79 - $0.84 216.0% - 236.0% * Millions ** Pro forma EPS excludes gain on debt extinguishment from both years, severance costs associated with workforce re-alignment in 2004 and write-off

  26. Slide 26: Why Invest in Kendle?

    Why Invest in Kendle? Significant improvement - Q2 2005 vs. Q2 2004 New business awards of $80 million, up 38 percent Total business authorizations of $273 million, up nearly 33 percent Net service revenues of $50 million, up 21 percent EPS of $0.10 per share, up 400 percent Continued strong cash fl

  27. Slide 27: Stock performance

    Kendle Stock performance KENOLE INTL INC a3 of 4-Aug-2005 20 5 600 c S Feneedinend FIRPA Dee lethal u 0 al Copyright. 2005 Yahoo! Inc. http://Finance yahoo .com/ North America + Europe + Asia/Pacific + Latin America® Africa aaa

  28. Slide 28: Real results.

    eal results.®

  29. Slide 29: Key Performance Indicators

    Key Performance Indicators 2004 Q1 2005 Q2 2005 New Revenue Growth Kendle 10.7% 16.9% 21.2% Peer Group 9.9% 13.5% 14.3% Operating Margin Comparison Kendle 3.9% 6.0% 7.3% Peer Group 13.5% 14.4% 12.1% Growth in Backlog Kendle 31.1% 32.0% 32.5% Peer Group 20.6% 18.8% 17.0% Net Book to Bill Kendle 1.32

Kendle International — Investor Presentation (August 2005) on 6ix